Author:
Xu Jiliang,Xu Chungui,Cao Ruifen,He Yonghui,Bin Yannan,Zheng Chun-Hou
Publisher
Springer Nature Singapore
Reference21 articles.
1. Plante, J.A., Mitchell, B.M., Plante, K.S., et al.: The variant gambit: COVID-19’s next move. Cell Host Microbe 29(4), 508–515 (2021)
2. Basith, S., Manavalan, B., Hwan Shin, T., et al.: Machine intelligence in peptide therapeutics: a next-generation tool for rapid disease screening. Med. Res. Rev. 40(4), 1276–1314 (2020)
3. Schütz, D., Ruiz-Blanco, Y.B., Münch, J., et al.: Peptide and peptide-based inhibitors of SARS-CoV-2 entry. Adv. Drug Deliv. Rev. 167, 47–65 (2020)
4. Beddingfield, B.J., Iwanaga, N., Chapagain, P.P., et al.: The integrin binding peptide, ATN-161, as a novel therapy for SARS-CoV-2 infection. Basic Transl. Sci. 6(1), 1–8 (2021)
5. Zhao, H., Meng, X., Peng, Z., et al.: Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. Emerg. Microbes Infect. 11(1), 926–937 (2022)